



CONTEXT









- Al applications in the pharmaceutical industry: lot of hype, but limited results
- Access to real-world data can be challenging for biopharmas
- Healthcare institutions want to monetise their data while respecting patient privacy

OWKIN WHO WE ARE

- International, multidisciplinary team talented in machine learning, biology and medicine
- Our data scientists are among the best in the world, with several Kaggle Masters (global top 100), a DREAM Challenge top performer and publications in ICML, NIPS and other top scientific journals.



THOMAS CLOZEL, MD

CEO

Assistant Professor and physician in clinical oncology.

Former PI at Weill Cornell.



GILLES WAINRIB, PhD

CSO

Professor of Machine Learning at Ecole Normale Supérieure. Postdoc at Stanford. Engineering degree from Ecole Polytechnique.



Data scientists



Developers



Physicians / bioinformaticians


OWKIN SOCRATES PLATFORM

An End-to-End Solution for Al-Enabled Healthcare Research Overcoming Data Sharing Obstacles

AUGMENT DOCTORS & RESEARCHERS SKILLS

OWKIN'S COLLECTIVE AI

EMPOWER PHARMA



Onsite Data

A



PHARMA

DRUG DISCOVERY & DEVELOPMENT

clinical trial optimization biomarker and target discovery

OWKIN NETWORK OF PARTNERSHIPS
















OWKIN HOW WE'RE DIFFERENT

FEDERATED LEARNING



Allows hospitals and/or biopharmas to collaborate without pooling or sharing any data.

Your data belongs to you. It doesn't end up in the cloud or transferred to our servers at anytime.

OWKIN OUR EXPERTISE

From images to omics, our unique integration pipeline can be used to connect the dots

Cancer

We create predictive models linking areas as diverse as biopsy site, resistance predictions and immunotherapy

Our expert knowledge builds off of our access to >500,000 patients in cancer centres in France

Pathology & Radiology



Using <u>CHOWDER</u>, a proprietary technology to analyse slides using deep learning



Genomics




Using deep learning to predict phenotypes by linking to pathology signals to genes

OWKIN MSI RESEARCH PROJECT


Through our network of partnerships, we are building an algorithm that can predict whether a patient is MSI-High using only their whole slide H&E histology

MSI Screening Today


- Systematic screening for cancers with frequent MSI-H phenotypes (colon & endometrial cancers)
- Case by case for other cancers
- Involves a long & costly testing process (IHC and/or PCR)




With MSI Socrates model




OWKIN MSI RESEARCH PROJECT



MSI-High tiles



MSS tiles



CURRENT CLIENTS







